UK markets open in 4 hours 16 minutes

Lyra Therapeutics, Inc. (LYRA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.2702+0.0086 (+3.29%)
At close: 04:00PM EDT
0.2700 -0.00 (-0.07%)
After hours: 07:27PM EDT
Full screen
Loading interactive chart…
  • GlobeNewswire

    Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital

    WATERTOWN, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced that it is advancing its goal to preserve capital by implementing a layoff of approximately 75% of its workforce, in addition to other cost-cutting measures. In the near term, Lyra Therapeutics will focus on the two ongoing ENLIGHTEN Phase 3 trials evaluating LYR-210, a bioabsorbable sinonasal implant for the treatment of chronic rhinosinusitis (CRS). Lyra continue

  • GlobeNewswire

    Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis

    ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forward WATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), today announced topline results from the Company’s Phase 3 ENLIGHTEN 1 trial evaluating LYR-210 for the treatment of chronic rhinosinusitis (CRS). ENLIGHTEN 1 did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in

  • Simply Wall St.

    Lyra Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

    Lyra Therapeutics ( NASDAQ:LYRA ) First Quarter 2024 Results Key Financial Results Net loss: US$22.5m (loss widened by...